Thermo Fisher Scientific Inc. (TMO)
Thermo Fisher Scientific (TMO) Q4 Earnings and Revenues Top Estimates
Thermo Fisher Scientific (TMO) came out with quarterly earnings of $6.10 per share, beating the Zacks Consensus Estimate of $5.93 per share. This compares to earnings of $5.67 per share a year ago.
Thermo Fisher beats quarterly estimates on strong demand for its tools and services
Thermo Fisher Scientific on Thursday beat Wall Street estimates for fourth-quarter profit and revenue, helped by improved demand for its products and services used in developing therapies.
Is Thermo Fisher Stock Worth Holding on to in Your Portfolio?
TMO continues to capture investors' attention due to its innovative product launches and trusted partnership status.
Thermo Fisher Scientific (TMO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Thermo Fisher (TMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Robust Analytical Instruments Segment Likely to Aid TMO's Q4 Earnings
Strength in Analytical Instruments and Specialty Diagnostics segments is likely to have driven Thermo Fisher's fourth-quarter 2024 performance.
Biologicals Is The Future In Thermo Fisher: Buy Rating
Thermo Fisher Scientific is poised for growth in 2025, driven by aging demographics, higher healthcare spending, and demand for innovative biological medicines. TMO's diverse revenue streams, including life sciences, analytical instruments, specialty diagnostics, and biopharma services, ensure stability and resilience against market cycles. Thermo Fisher is a good bet for a well diversified portfolio.
Will Thermo Fisher (TMO) Beat Estimates Again in Its Next Earnings Report?
Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Thermo Fisher Scientific Inc. (TMO) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
Thermo Fisher Scientific Inc. (NYSE:TMO ) 43rd Annual J.P. Morgan Healthcare Conference Call January 14, 2025 11:15 AM ET Company Participants Marc Casper - Chief Executive Officer Conference Call Participants Rachel Vatnsdal - JPMorgan Rachel Vatnsdal Perfect.
Macroeconomic Woes, Competition Weigh on TMO's Stock Performance
The industry-wide trend of difficult macroeconomic conditions is creating a challenging business environment for Thermo Fisher.
Bioproduction Prospects to Drive TMO Shares Despite Macroeconomic Woes
TMO's recent strategic acquisitions, including the $3.1-billion acquisition of Olink Holdings, are likely to drive future growth.
Thermo Fisher: The Cycle Has Already Turned Around
Thermo Fisher's stock is now a "buy" due to signs of recovery, including positive sales growth and stabilized margins, despite recent bearish trends. The company's post-pandemic challenges are easing, with optimistic executive comments and improved guidance for 2024, indicating a potential return to organic growth. Potential deregulation under Trump's administration could benefit Thermo Fisher by increasing demand for its equipment and consumables in a more competitive pharmaceutical market.
TMO Institutional & Insider Stock Sell-Offs Upset Market: How to Play
Investors are also concerned about Thermo Fisher's continuous decline in testing revenues due to the decline in COVID testing-related demand.
